Revvity (NYSE:RVTY) CAO Sells $13,060.32 in Stock

October 3, 2026 by InsiderTrades.com

Key Points

Insider sale: Chief Accounting Officer Anita Gonzales sold 84 Revvity shares for $13,060.32, reducing her holdings by 1.17% to 7,117 shares.
Strong quarterly results: Revvity reported adjusted EPS of $1.41, exceeding estimates of $1.21, while revenue reached $729.69 million. The company reaffirmed fiscal 2026 EPS guidance of $5.30–$5.40.
Mixed market outlook: Analysts have a consensus “Hold” rating with a $116.57 target price, below the stock’s recent $151.46 price; Revvity also announced a quarterly dividend of $0.07 per share.

Revvity Inc. (NYSE:RVTY - Get Free Report) CAO Anita Gonzales sold 84 shares of Revvity stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $155.48, for a total value of $13,060.32. Following the sale, the chief accounting officer owned 7,117 shares of the company's stock, valued at approximately $1,106,551.16. This represents a 1.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Anita Gonzales also recently made the following trade(s):

On Monday, July 20th, Anita Gonzales sold 85 shares of Revvity stock. The shares were sold at an average price of $109.48, for a total transaction of $9,305.80.

Revvity Price Performance

NYSE:RVTY opened at $151.46 on Friday. The firm has a market cap of $16.90 billion, a price-to-earnings ratio of 72.13, a price-to-earnings-growth ratio of 2.71 and a beta of 1.06. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36. The company's 50-day moving average is $128.26 and its two-hundred day moving average is $108.70. Revvity Inc. has a 12-month low of $81.22 and a 12-month high of $158.28.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.21 by $0.20. The business had revenue of $729.69 million during the quarter, compared to the consensus estimate of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The company's quarterly revenue was down 1.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts expect that Revvity Inc. will post 5.36 EPS for the current year.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be given a dividend of $0.07 per share. The ex-dividend date is Friday, October 23rd. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. Revvity's dividend payout ratio (DPR) is 13.33%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. QRG Capital Management Inc. increased its position in Revvity by 14.4% during the 2nd quarter. QRG Capital Management Inc. now owns 5,881 shares of the company's stock worth $654,000 after purchasing an additional 742 shares in the last quarter. State Street Corp grew its position in Revvity by 0.8% in the second quarter. State Street Corp now owns 4,342,739 shares of the company's stock valued at $483,173,000 after acquiring an additional 32,426 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Revvity by 5.8% during the second quarter. The Manufacturers Life Insurance Company now owns 368,938 shares of the company's stock valued at $41,048,000 after purchasing an additional 20,278 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in shares of Revvity during the second quarter valued at approximately $171,000. Finally, Nykredit A S acquired a new position in shares of Revvity during the second quarter worth $358,000. Institutional investors and hedge funds own 86.65% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on RVTY shares. Wall Street Zen downgraded Revvity from a "buy" rating to a "hold" rating in a report on Sunday, August 16th. UBS Group started coverage on Revvity in a report on Wednesday, September 9th. They set a "neutral" rating and a $140.00 price objective on the stock. Weiss Ratings raised Revvity from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, July 30th. KeyCorp upped their target price on Revvity from $125.00 to $165.00 and gave the company an "overweight" rating in a research note on Friday, September 4th. Finally, Evercore reiterated an "outperform" rating on shares of Revvity in a research report on Wednesday, August 5th. Four equities research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company's stock. According to data from MarketBeat, Revvity presently has an average rating of "Hold" and a consensus target price of $116.57.

Get Our Latest Analysis on RVTY

Revvity Company Profile

(Get Free Report)

Revvity, Inc (NYSE:RVTY) is a life sciences and diagnostics company that provides technologies, products and services used in biological research, drug discovery, clinical testing and healthcare. The company serves pharmaceutical and biotechnology companies, academic and government research institutions, hospitals, clinical laboratories and other healthcare organizations.

Its portfolio includes instruments, reagents, consumables, software and related services for areas such as genomics, proteomics, cellular analysis, imaging and multiplex testing.